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Abstract
Objective: Insulin and the insulin-like growth factor (IGF) system regulate growth and are involved in determining muscle
mass, strength and body composition. We hypothesised that IGF-I and IGF-II are associated with improved, and insulin with
worse, physical performance in old age.
Methods: Physical performance was measured using the get-up and go timed walk and flamingo balance test at 63–86
years. We examined prospective associations of insulin, IGF-I, IGF-II and IGFBP-3 with physical performance in the UK-based
Caerphilly Prospective Study (CaPS; n = 739 men); and cross-sectional insulin, IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in the Boyd
Orr cohort (n = 182 men, 223 women).
Results: In confounder-adjusted models, there was some evidence in CaPS that a standard deviation (SD) increase in IGF-I
was associated with 1.5% faster get-up and go test times (95% CI: 20.2%, 3.2%; p = 0.08), but little association with poor
balance, 19 years later. Coefficients in Boyd Orr were in the same direction as CaPS, but consistent with chance. Higher levels
of insulin were weakly associated with worse physical performance (CaPS and Boyd Orr combined: get-up and go
time= 1.3% slower per SD log-transformed insulin; 95% CI: 0.0%, 2.7%; p = 0.07; OR poor balance 1.13; 95% CI; 0.98, 1.29;
p = 0.08), although associations were attenuated after controlling for body mass index (BMI) and co-morbidities. In Boyd Orr,
a one SD increase in IGFBP-2 was associated with 2.6% slower get-up and go times (95% CI: 0.4%, 4.8% slower; p = 0.02), but
this was only seen when controlling for BMI and co-morbidities. There was no consistent evidence of associations of IGF-II,
or IGFBP-3 with physical performance.
Conclusions: There was some evidence that high IGF-I and low insulin levels in middle-age were associated with improved
physical performance in old age, but estimates were imprecise. Larger cohorts are required to confirm or refute the findings.
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Introduction
Increasing life expectancy in the UK has provoked public health
concern about the prospects of a growing number of people
experiencing functional limitations in old age. Understanding the
causes of poor physical functioning and the identification of
potential prevention strategies are critically important public
health issues. One possible pathway contributing to poor physical
functioning is the insulin-like growth factor (IGF) system. The IGF
family contains two peptide hormones, or growth factors: IGF-I
and IGF-II; and six binding proteins IGFBP-1 to -6 that modulate
IGF activity [1]. Ageing is associated with a decline in levels of
IGF-I, which may reflect decreases in growth hormone production
with age [2]. The IGF system is involved in body composition,
muscle maintenance and bone cell survival [3] and might
influence measures of physical function in old age via a loss of
muscle mass and strength [4]. A previous cross-sectional study
indicates that high levels of IGF-I are weakly associated with faster
walking speed [5] but results have not always been consistent [6,7].
Other components of the IGF system may also be associated with
functional ability with age: high IGF-I increases sensitivity to
insulin [8] which may in turn be related to increased muscle
strength [9]; circulating levels of IGFBP-2 are reduced in people
with obesity [10] and insulin resistance [7,11,12] and may mediate
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associations of obesity and insulin resistance with poor physical
functioning; higher circulating IGFBP-3 lowers the bioavailability
of IGF-I, so may be associated with poorer physical performance,
although, IGFBPs are thought to exert both positive and negative
regulatory effects on IGF activity [13]. The role of IGF-II is less
well known, although it has been suggested to play a critical role in
muscle regeneration, and relatively higher IGF-II levels may
prevent the age-related decline in muscle mass [14]. Understand-
ing the role of the insulin-IGF system in physical performance has
potential public health implications because it is nutritionally
regulated, e.g. higher milk intake increases IGF-I [15], and IGFs
are linked with other lifestyle factors, e.g. IGF-I and IGFBP-3 have
been positively associated with increased physical activity and
reduced cigarette smoking [16], so may be potentially modifiable.
Cross sectional studies cannot demonstrate the direction of
association but prospective studies to investigate associations of the
IGF system with physical performance have not been conducted to
date. Here we examine prospective associations of the IGF system
and physical performance 19 years later in the Caerphilly
Prospective Study (CaPS) and compare these to cross-sectional
associations of the IGF system and physical performance in old
age in the Boyd Orr cohort. Our a priori hypothesis was that low
levels of IGF-I and IGF-II and higher levels of insulin would be
associated with reduced physical performance in old age.
Materials and Methods
Participants
The Boyd Orr study is an historical cohort based on the
Carnegie (Boyd Orr) Survey of Diet and Health in Pre-War
Britain, 1937–1939 [17]. In the original survey, 4,999 boys and
girls aged 0–19 years in 16 centers across the UK underwent
physical measurements, the family completed a week-long dietary
inventory and detailed assessments of socioeconomic environment
were made. Ethical approval for the Boyd Orr study was obtained
from the Multicentre Research Ethics Committee for Scotland. In
1997, a follow-up study re-established contact with the subjects
using the National Health Service Central Register and its
equivalent in Edinburgh. The follow-up study identified 3,182
individuals from the original sample of families who were traced,
alive and residing in Britain. These subjects were sent a detailed
health and lifestyle questionnaire and 1,648 responses were
received. In 2002, all 732 surviving study members aged 63–83
years who lived near clinics in Bristol, London, Wisbech,
Aberdeen and Dundee, and had previously consented to clinical
follow-up, were contacted; of these 405 (55%) - 182 men and 223
women - agreed to take part in a detailed clinical examination and
questionnaire, where fasting blood samples were taken and the get-
up and go walking speed [18] and flamingo balance [19] physical
performance tests were carried out.
The Caerphilly Prospective Study (CaPS) recruited 2,512 men
aged 45–59 years between 1979 and 1983 from the town of
Caerphilly, South Wales and the adjacent villages (http://www.
epi.bris.ac.uk/caerphilly/caerphillyprospectivestudy.htm) [20].
Ethical approval for the different phases of the study was given
by the Ethics Committee of the Division of Medicine of the former
South Glamorgan Area Health Authority and Gwent Research
Ethics Committee. For the second examination (phase II 1984–
1988), the original cohort was supplemented with 447 men of a
similar age who had moved into the defined area; however, 561
men were lost from the cohort giving a total of 2,398 men who
participated in phase II. Since then, the men have been examined
on three further occasions: phases III (1989–1993), IV (1993–
1996) and V (2002–2004). At each phase, the men completed
lifestyle questionnaires and fasting blood samples were taken. A
total of 1,195 men aged 66–86 years attended the phase V clinic
(or had a home visit) where the physical performance tests were
undertaken. All participants in both cohorts gave informed written
consent.
Measurement of physical performance
The get-up and go test. This is a standardized objective
measure of functional leg strength, power, mobility and balance
that is strongly correlated with activities of daily living and
integrates a number of basic mobility movements considered
necessary for successful ageing and protection from disability [18].
The participant is timed while they rise from a chair, walk three
meters, turn, walk back to the chair and sit down. The test was
performed on each person twice and the mean value used in the
analysis to minimize measurement error.
The flamingo test. Measures the ability to maintain postural
stability in the upright position, a pre-requisite for locomotor
mobility [19]. The flamingo test was performed by timing how
long subjects could lift one leg, whilst the other leg remained
straight, with their eyes open. The position was held for as long as
possible, for a maximum of 30 seconds. Participants used their
preferred leg to stand on. The flamingo test was performed twice,
unless the maximum score of 30 seconds was achieved in the first
attempt. The best score was used in the analysis. The tests were
measured using the same standardized protocol in both cohorts
and the researchers trained by the same investigator (RMM).
Measurement of insulin and insulin-like growth factors
In Boyd Orr, IGF-I and IGF-II, the major binding proteins
(IGFBP-2 and IGFBP-3) and insulin were measured from blood
samples taken from the 405 participants in the 2002 clinic.
Samples were taken after an overnight fast. The samples were
spun and frozen to 220uC within one hour and transferred within
three weeks to a 280uC freezer [21]. In CaPS, fasting insulin was
assayed for previous studies and was measured using a
radioimmunoassay based on a double antibody for insulin,
available for 1,005 men with physical performance data. Insulin
was used from phase I if available, or if the men did not attend
phase I, data from phase II was used (n = 186). Serum IGF-I, IGF-
II and IGFBP-3 were measured on 739 samples stored at 280uC
and selected from phase II, approximately 19 years prior to the
physical performance tests. Serum IGF-I, IGF-II, and IGFBP-3
levels were measured using in-house double-antibody radio
immunoassays in both cohorts [22]. The radioimmunoassay
measures total IGF-I and IGF-II levels, including all forms that
have undergone minor fragmentation. In Boyd Orr, total levels of
IGFBP-2 were measured by one-step sandwich enzyme-linked
immunosorbent assays (DSL-10-7100; Diagnostic Systems Labo-
ratories, Webster, TX); insulin was measured with an insulin-
specific assay that does not cross-react with proinsulin and split
forms of proinsulin. In Boyd Orr, the average coefficients of
variation for intraassay variability for IGF-I, IGF-II, IGFBP-3,
and IGFBP-2 were 6.7, 10.0, 3.9, and 5.0% and for interassay
variation were 9.7, 14.0, 8.1, and 7.1%. Interassay coefficients of
variation were 5.3%, 4.2% and 4.4% for low, medium and high
values of insulin. In CaPS, the average coefficients of variation for
intraassay variability for IGF-I, IGF-II, IGFBP-3 and phase II
insulin were 7.0, 7.9, 5.6 and 7.5% and for interassay variation
were 8.8, 9.7, 8.8 and 8.9%.
Measurement of potential confounders
Information on potential confounders was collected from
questionnaires administered at research clinics; in Boyd Orr this
Insulin, IGFs and Physical Performance
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was from 1997 and 2002, and in CaPS this was from phases I
(1979–1983), II (1984–1988) and III (1989–1993) and has been
described in detail previously [23]. In Boyd Orr, adult social class
was recorded in 1997 and corresponded to the job participants
spent most of their working lives. For men, adult social class was
classified into categories based on the 1966 Classification of
Occupations. For women, the social class of their spouse or
partner was used, if available, otherwise their own occupation was
used. Adult social class was classified into three categories in Boyd
Orr (I/II, professional and managerial; III, skilled; IV/V, partly
skilled, unskilled, other or unclassifiable). In CaPS, social class in
adulthood was based on participants’ present or last job at phase II
(1984–1988) and divided into four categories (I/II, professional
and managerial; III, skilled non-manual; III, skilled manual; IV/
V, partly skilled, unskilled, other or unclassifiable). Health
behaviors were recorded at the 2002 Boyd Orr clinic and CaPS
phase II. Questions on smoking behavior were used to assign
people into three groups (current; past; and never smokers).
Alcohol consumption was coded into three groups (frequent [at
least weekly]; occasional; and never). Exercise scores were derived
from questions on the frequency physical activities were carried
out. The overall scores were split into three approximately equal
sized groups ranging from least to most exercise. Adult diet was
estimated from food frequency questionnaires and averaged over
multiple time periods to reduce measurement error (Boyd Orr
1997 and 2002; CaPS phases I to III). To calculate nutrient intake,
frequency of consumption of a food was multiplied by the nutrient
content of a standard portion of that food using food tables [24]. In
CaPS, the average portion sizes used were calculated from seven-
day weighed dietary records completed by a one-third sample of
the Caerphilly cohort at phase I [25]. Milk consumption, calcium,
protein, fat and energy intake have been linked to IGFs in many
cohorts [15,26–28], so these were considered as potential dietary
confounding variables. Intake of milk was split into four groups
ranging from lowest to highest intake; calcium, protein, fat and
energy intake were considered as continuous variables.
Measurement of body mass index and co-morbidities
Body mass index (BMI) was derived from height and weight
measurements (weight [kg]/height [m]2), which were recorded at
the research clinics when the blood samples were taken. We
control for BMI because a previous study in the Boyd Orr cohort
found a negative association between BMI and IGFBP-2, an
inverted U-shape relationship between BMI and IGF-I, and a
positive relationship of BMI with IGF-II and insulin [12].
Increased BMI was associated with slower walking times and
poor balance in both cohorts [23]. Information on major co-
morbidities (stroke, cancer, diabetes and angina) was collected
from self-reported questionnaires. Derived variables were created
to indicate a diagnosis of each disease by the time of the physical
performance examination. In Boyd Orr: a diagnosis of diabetes
was derived from a combination of self-report and fasting glucose
measurement; cancer prevalence at the time of the measurement
of physical performance was based on either self-reported cancer
or a notification of cancer registration received from the National
Health Service Central Register. Angina was based on the Rose
chest pain questionnaire [29].
Statistical analyses
All analyses were carried out using Stata version 11. IGF values
and levels of insulin were converted into z-scores, which accounted
for any baseline and laboratory related variation in IGF levels: age
at blood sample; sex (Boyd Orr); duration of sample storage time;
the laboratory technician who performed the assays (CaPS); and
the week of the assay (CaPS). The z-scores have a mean of zero
and a standard deviation (SD) of one, enabling the comparison for
an equivalent one SD change in each IGF measurement. Due to
skewed distributions, IGFBP-2 and insulin and were natural log
transformed before the z-scores were created. The IGF-I:BP-3
molar ratio may be a marker of IGF-I bioavailability. Based on the
molecular weight of IGF-I (7500) and IGFBP-3 (40,000, mean of
glycosylated variants), the molar ratio was calculated by
multiplying IGF-I:BP-3 by 5.33 (40,000:7500) [21]. Blood samples
for IGF measurements (CaPS phase II) were only available for 739
men with the physical performance outcomes (CaPS phase V).
Any differences for those with and without stored blood samples
were examined with chi-squared tests. Correlations between
continuous variables were calculated using Pearson’s correlation
coefficients.
Walking times from the get-up and go test were natural log-
transformed, due to a skewed distribution. Linear regression
models were used to investigate associations of IGFs with the log-
transformed walking time and regression coefficients were
multiplied by 100 to represent percentage change in walk time
[30]. Since a longer time to complete the get-up and go test implies
person was slower, a positive coefficient of percentage change
represents a slower walking time and a negative estimated coefficient
of percentage change represents a faster walking time. Over a third
of participants achieved the maximum balance of 30 seconds;
therefore, the flamingo test was dichotomized at the lowest 20% of
performers, using a cut-point of five seconds. The flamingo test
was modeled using logistic regression, with the outcome of interest
being the inability to balance for five seconds (coded with a value
of one in models and termed ‘poor balance’ in the text). We tested
for interactions between the cohorts to assess whether it was
suitable to pool the data. Minimally adjusted models control for
age at the time of the physical performance test and sex (Boyd
Orr); further adjusted models additionally control for research
centre, adult social class, diet, exercise, smoking status and alcohol
consumption; final models also controlled for BMI and co-
morbidities (stroke, cancer diabetes and angina) at the time of the
IGF measurement. Non-linear associations for the IGF variables
were investigated by comparing models with and without
quadratic terms.
Results
Descriptive statistics for the outcomes, exposures and potential
confounding variables are shown in Table 1. In Boyd Orr, the
physical performance tests and IGF measurements were carried
out when the participants were a mean age of 70.7 years (inter-
quartile range [IQR] 67–74; range 63–83 years). CaPS men were
older at the time of the physical performance tests (mean age 75.3;
IQR 71–78; range 66–86 years) and their blood samples for the
IGF measurements were taken approximately 19 years earlier
(mean age 56.1; IQR 52–60; range 47–67 years).
Blood samples from CaPS phase II were available for 739 (62%)
of the 1,195 men who attended the CaPS phase V clinic. There
were no important differences in potential confounders (e.g. age,
smoking, social class, alcohol use, physical activity) for those with
and without blood samples. IGF-I was positively correlated with
IGF-II and IGFBP-3, but inversely correlated with IGFBP-2
(Table 2). IGF-II was positively correlated with IGFBP-3 and
negatively correlated with IGFBP-2. The IGF binding proteins
were negatively correlated with each other and IGFBP-2 was
negatively correlated with insulin. Associations of social class and
lifestyle factors have already been published for these cohorts,
briefly, more deprived social class, cigarette smoking, lower levels
Insulin, IGFs and Physical Performance
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Table 1. Characteristics of study members.
Mean (SD); median (quartiles)*; or N (%)
N Boyd Orr N CaPS
Outcomes
Get-up and go test (seconds)* 405 9.3 (8.2, 10.8) 1114 10.3 (9.0, 12.2)
Flamingo test (balance ,5 seconds) 404 81 (20%) 1123 290 (26%)
Exposures
IGF-I (ng/ml) 405 131.4 (40.9) 739 155.4 (48.1)
IGF-II (ng/ml) 405 746.6 (226.4) 739 719.1 (238.1)
IGFBP-2 (ng/ml)* 405 415.0 (280.0, 597.3) -
IGFBP-3 (ng/ml) 405 4138.2 (1008.7) 739 3387.8 (757.9)
Insulin (mu/l)* 370 7.8 (5.4, 12.5) 1005 5.3 (3.3, 9.0)
Potential confounders
Age at clinic where blood sample was taken (years) 405 70.7 (4.3) 1195 56.1 (4.4)
Age at performance tests (years) 405 70.7 (4.3) 1195 75.3 (4.3)
Sex (male) 405 182 (45%) 1195 1195 (100%)
Adult social class 399 928
I/II 28 (7%) 77 (8%)
III NM{ } 97 (24%) 55 (6%)
III M{ 591 (64%)
IV/V/Other{ 192 (48%) 166 (18%)
Unemployed 82 (21%) 39 (4%)
Smoking status 405 1139
Current 43 (11%) 407 (36%)
Past 198 (49%) 470 (41%)
Never 164 (40%) 262 (23%)
Alcohol consumption 404 1141
At least weekly 196 (49%) 790 (69%)
Occasionally 152 (38%) 286 (25%)
Never 56 (14%) 65 (6%)
Exercise group 404 1141
1 (Least) 130 (32%) 329 (29%)
2 121 (30%) 423 (37%
3 (Most) 153 (38%) 389 (34%)
Adult diet
Calcium (mg) 405 1109 (373) 1190 926 (219)
Protein (g) 405 88 (25) 1193 72 (14)
Fat (g) 405 76 (30) 1192 87 (22)
Total energy (kcal) 402 2206 (697) 1190 2109 (452)
Milk group1 395 1193
Milk group: none 11 (3%) 130 (11%)
Less than half a pint 101 (25%) 621 (52%)
Half a pint to a pint 196 (48%) 398 (33%)
More than a pint 97 (24%) 44 (4%)
BMI (kg/m2) 405 27.5 (4.4) 1178 26.6 (3.4)
Stroke 403 22 (5.5%) 1102 131 (11.9%)
Insulin, IGFs and Physical Performance
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of exercise, greater BMI, and a history of stroke and angina were
all associated with worse physical performance.
Associations of insulin and IGFs with the get-up and go
test
All participants in CaPS were male and there was no evidence
of a sex-interaction for IGFs with physical performance in Boyd
Orr (p-values for the interaction terms ranged from 0.2 for IGF-II
to 0.9 for IGF-I); therefore, data were pooled for men and women.
In CaPS, a one SD increase in IGF-I was associated with a 2.0%
faster get-up and go time after 19 years’ follow-up in minimally-
adjusted models (95% CI 0.4%, 3.7%; p= 0.017) (Table 3). In the
cross-sectional Boyd Orr analysis there was a 1.1% faster get-up
and go time per SD increase in IGF-I. However, the confidence
interval was consistent with chance (95% CI 1.3% slower, 3.6%
faster; p = 0.4). There was no evidence of an interaction between
cohorts (Boyd Orr and CaPS) and associations of IGF-I with the
get-up and go test, so the data were pooled (p interaction= 0.5).
The combined estimate for a SD change in IGF-I was a 1.7%
faster get-up and go time (95% CI 0.3%, 3.1% faster; p = 0.017).
The coefficient was attenuated to 1.2% faster get-up and go time
(0.2% slower, 2.3% faster; p = 0.09) when controlling for
confounding variables and to 1.0% faster get-up and go time
(95% CI 0.3% slower, 2.4% faster; p = 0.14) after controlling for
BMI and co-morbidities (stroke, cancer, diabetes and angina).
There was no evidence of a non-linear association between IGF-I
and the get-up and go test (p for including a quadratic term=0.4
in Boyd Orr; p = 0.7 CaPS). There was no evidence of an
association between IGF-II and the get-up and go test in either
cohort. In Boyd Orr, a one SD increase in IGFBP-2 was associated
with 2.6% slower get-up and go times (95% CI 0.4%, 4.8% slower;
p = 0.021), but this was only seen when controlling for BMI and
co-morbidities. In Boyd Orr, a one SD increase IGFBP-3 in old
age was associated with a 3.0% faster get-up and go time (95% CI
0.9%, 5.2% faster; p = 0.007) in fully adjusted models. There was
no evidence of any association between IGFBP-3 and get-up and
go time in CaPS and there was evidence of a difference between
the Boyd Orr and CaPS studies (p interaction= 0.012). A one SD
increase in insulin was associated with a 1.3% slower get-up and
go time in the confounder-adjusted model (pooled data; 95% CI
0.0%, 2.7%; p= 0.07), but this was attenuated after adjustment for
BMI and co-morbidities (coefficient 0.3% faster; 95% CI 1.1%
slower, 1.8% faster; p = 0.6). Mutually controlling for IGF-I and
insulin did not alter findings (results not shown).
Associations of insulin and IGFs with the flamingo test
Associations of the insulin-IGF system with the flamingo test are
shown in Table 4. The estimated odds suggest a lower risk of poor
balance for a one SD increase in IGF-I, but the confidence
intervals are consistent with chance (Boyd Orr OR=0.88 in age-
and sex-adjusted model; 95% CI 0.65, 1.20; p = 0.4; CaPS
OR=0.87; 0.73, 1.04; p = 0.13). There was no evidence of an
interaction for the associations of IGF-I and cohort for balance
ability so the data were pooled (p interaction = 0.9). The combined
estimate gave an odds ratio of poor balance of 0.87 (95% CI 0.75,
1.01; p = 0.08). The estimated odds ratio was only slightly
attenuated when socioeconomic position, diet, health behaviors,
BMI and co-morbidities were controlled for. There was no
evidence of associations of IGF-II, IGFBP-2, IGFBP-3 or the IGF-
I:BP-3 molar ratio with balance ability in either cohort, or when
data were pooled across cohorts (Table 4). In CaPS, a one SD
increase in log transformed insulin was associated with a higher
Mean (SD); median (quartiles)*; or N (%)
N Boyd Orr N CaPS
Cancer 405 58 (14.3%) 1100 150 (13.6%)
Diabetes 402 39 (9.7%) 1096 158 (14.4%)
Angina 401 75 (18.7%) 1090 236 (21.7%)
Note: sample sizes vary due to missing data. Blood samples from CaPS phase II for IGFs were only available for 739 (62%) of the 1,195 men who attended the CaPS phase
V clinic.
SD = Standard deviation.
*Median and quartiles are presented, due to skewed distributions; the mean (SD) for IGFBP-2 was: 484.2 (292.3) ng/ml and for insulin: 10.0 (6.9) mu/l in Boyd Orr; 7.6
(14.8) mu/l in CaPS.
{Data are not available to distinguish between the social classes III manual (M) and III non-manual (NM) in Boyd Orr.
{Armed forces, unemployed or unclassifiable.
1Milk groups range from lowest to highest intake: none, K pint (,237 g) or less, K pint (,237 g) to one pint (,473 g), more than one pint (,473 g).
doi:10.1371/journal.pone.0030096.t001
Table 1. Cont.
Table 2. Pearson correlation coefficients of the insulin-like
growth factor system in Boyd Orr and CaPS.
Correlation coefficient (p value)
IGF-I IGF-II IGFBP-2* IGFBP-3
IGF-II
Boyd Orr 0.39 (,0.001)
CaPS 0.27 (,0.001)
IGFBP-2*
Boyd Orr 20.19 (,0.001) 20.28 (,0.001)
CaPS - -
IGFBP-3
Boyd Orr 0.57 (,0.001) 0.63 (,0.001) 20.23 (,0.001)
CaPS 0.39 (,0.001) 0.34 (,0.001) -
Insulin*
Boyd Orr 0.06 (0.3) 0.12 (0.021) 20.44 (,0.001) 0.09 (0.09)
CaPS 20.02 (0.7) 20.01 (0.9) - 0.03 (0.4)
The IGFs and insulin were standardized by: age, sex (Boyd Orr), sample storage
time and lab technician (CaPS).
*IGFBP-2 and insulin were natural log transformed before standardization, due
to skewed distributions; IGFBP-2 is only available in Boyd Orr.
doi:10.1371/journal.pone.0030096.t002
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odds of poor balance (OR 1.16; 95% CI 0.99, 1.35; p= 0.059). A
similar association for insulin was not observed in Boyd Orr (p
interaction = 0.6; giving a pooled estimate of 1.13; 95% CI 0.98,
1.29; p = 0.08 in confounder-adjusted models), which was
attenuated when BMI and co-morbidities were controlled for.
Mutually controlling for IGF-I and insulin did not alter findings
(results not shown).
Discussion
This is the first study to suggest that higher IGF-I and lower
insulin levels measured in mid-life are prospectively associated
with improvements in objective assessments of physical perfor-
mance measured decades later, although the effect estimates were
imprecisely estimated (with wide confidence intervals) and so
inferences from this study must be made with caution. The
associations for insulin were explained by BMI and co-morbidities,
though we cannot be certain whether BMI was the upstream
determinant of raised insulin or vice versa. There were no
associations with IGF-II in either cohort. An association between
high IGFBP-2 and slower get-up and go speed was only observed
when BMI and co-morbidities were controlled for, so should be
interpreted with caution. In the cross-sectional analyses (Boyd
Orr), higher levels of IGFBP-3 were associated with faster get-up
and go times, but this was not seen in the prospective analyses
(CaPS).
The results from CaPS provide some evidence to support the
hypothesis that IGF-I is positively associated with levels of physical
function in old age, although results from Boyd Orr were
consistent with chance. Other studies investigating cross-sectional
associations of IGF-I with walking speed have produced conflicting
results, with studies showing weak positive effects [5], little
association [6], no evidence of an association [7] or a negative
association in the oldest-old men [31]. However, IGF-I was
strongly positively associated with knee extensor strength in 667
women aged 70–79 years (p = 0.004) [5]. In line with our findings,
IGFBP-2 has previously been linked with lower physical
performance in a cross-sectional study, which also controlled for
BMI [7]. Van den Beld et al. speculated that IGFBP-2 was related
to physical performance because it inversely reflected nutritional
status (i.e. high IGFBP-2 reflects worse nutritional status) and the
biological effects of growth hormone, IGF-I and insulin [7]. In our
study an association between IGFBP-2 and the get-up and go test
was unmasked when BMI was controlled for, because IGFBP-2
was inversely associated with BMI [12], and in turn, BMI was
inversely associated with physical performance [23]. Studies
Table 3. Associations of age- and sex-standardized IGF z-scores and percentage change in time to complete the get-up and go
test from linear regression models.
Boyd Orr (cross-sectional associations{) CaPS (prospective associations{) Boyd Orr and CaPS combined{
IGF z-score %1 95% CI P %1 95% CI P %1 95% CI P
Minimally adjusted models"
IGF-I 21.1% (23.6, 1.3) 0.4 22.0% (23.7, 20.4) 0.017 21.7% (23.1, 20.3) 0.017
IGF-II 0.1% (22.4, 2.6) 0.9 0.3% (21.4, 2.0) 0.7 0.2% (21.2, 1.7) 0.7
IGFBP-2* 0.4% (21.8, 2.7) 0.8 - - - - - -
IGFBP-3 23.1% (25.8, 20.6) 0.020 0.5% (21.1, 2.3) 0.8 - - -
IGF-I:BP-3 1.6% (20.8, 4.11) 0.2 22.1% (23.8, 20.5) 0.031 - - -
Insulin* 2.5% (20.2, 5.3) 0.068 0.7% (20.9, 2.4) 0.3 1.3% (0.0, 2.7) 0.076
Confounder adjusted models"
IGF-I 20.4% (22.9, 1.9) 0.7 21.5% (23.2, 0.2) 0.08 21.2% (22.6, 0.2) 0.09
IGF-II 20.1% (22.4, 2.0) 0.8 0.3% (21.3, 2.1) 0.6 0.3% (21.1, 1.7) 0.7
IGFBP-2* 0.0% (22.1, 2.1) 1.0 - - - - - -
IGFBP-3 22.8% (25.1, 20.6) 0.013 0.7% (20.9, 2.5) 0.4 - - -
IGF-I:BP-3 2.1% (20.2, 4.5) 0.08 21.7% (23.4, 20.1) 0.042 - - -
Insulin* 1.3% (21.1, 3.8) 0.3 1.1% (20.6, 2.8) 0.19 1.3% (0.0, 2.7) 0.07
Additionally controlling for BMI and co-morbidities"
IGF-I 20.1% (22.3, 2.2) 0.9 21.2% (22.9, 0.4) 0.14 21.0% (22.4, 0.3) 0.14
IGF-II 20.6% (22.8, 1.6) 0.5 20.2% (21.8, 1.5) 0.8 20.2% (21.6, 1.2) 0.8
IGFBP-2* 2.6% (0.4, 4.8) 0.021 - - - - - -
IGFBP-3 23.0% (25.2, 20.9) 0.007 0.1% (21.5, 1.8) 0.9 - - -
IGF-I:BP-3 2.6% (0.4, 4.9) 0.020 21.1% (22.8, 0.5) 0.19 - - -
Insulin* 21.4% (24.1, 1.3) 0.3 0.3% (21.5, 1.7) 0.9 20.3% (21.8, 1.1) 0.6
*IGFBP-2 and insulin were natural log transformed before standardizing due to skewed distributions.
{Sample sizes are based on complete-case analyses for all confounders: Boyd Orr IGFs n = 393, insulin n = 359; CaPS IGFs n = 722, insulin n = 950.
{Data were combined if there was no evidence the association differed between the cohorts.
1The natural log transformation was used on the get-up and go test. Coefficients are interpreted as % change in time per SD change in IGF; a positive % change
indicates a slower walk time; a negative % change indicates a faster walk time.
"Minimal adjusted models control for age at performance test and sex (Boyd Orr); confounder adjusted models additionally control for research centre, adult social class,
diet variables (milk intake, calcium, protein, fat and total energy), exercise, smoking, alcohol consumption; fully adjusted models additionally control for body mass
index (BMI) at the time of IGF measurement and co-morbidities at the time of the physical performance tests.
doi:10.1371/journal.pone.0030096.t003
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investigating IGFBP-3 with walking speed have not found
evidence of an association [6,32], although IGFBP-3 has been
suggested as an indicator of increased catabolism and wasting [33].
The National Health and Nutrition Examination Survey found
that higher levels of insulin resistance were associated with slower
walking speed in men, in a cross-sectional analysis [34]. Results
from the Cardiovascular Health Study showed that higher levels of
insulin resistance were associated with markers of frailty (which
included an element of slow walking speed) over 9 years’ follow-up
[35].
IGF-I has a wide range of biological effects on many different
tissues, including inhibiting protein degradation in muscle [1].
Therefore, declining IGF-I with age may contribute to loss of
muscle strength and reduced physical performance in older adults
for tasks that involve power. Results from the Women’s Health
and Aging Study I and II (cross-sectional data for 728 women aged
70 to 79 years) showed a positive relationship between IGF-I levels
and walking speed for IGF-I levels below 50 ng/ml, but only a
weak relationship above this threshold [5]. The mechanisms
linking insulin with reduced physical performance and frailty are
uncertain, but may involve an influence on muscle strength [9].
A main strength of the studies is the objective measures of
physical performance, which are known to be associated with risk
of falls, progression to disability [36], and death [37] in older
people. When there was no evidence of an interaction between
studies the data were pooled to increase power. IGFs in CaPS
were measured on blood samples taken approximately 19 years
prior to the physical performance tests, enabling prospective
associations to be examined. However, the blood samples were
stored in freezers from the time the samples were taken (from 1984
to 1988) to the assay measurement (in 2009). This long storage
time may have had an effect on samples; however, mean levels
were in line with IGF levels seen in other samples of men with a
similar age distribution [10,11] and stability studies indicate that
IGF levels are stable when stored for 9 years at 280uC [38]. It is
likely that any misclassification of IGFs related to storage
deterioration would have been random, attenuating observed
associations towards the null. A disadvantage in both cohorts is
that IGFs were only measured once for each person. However,
levels of IGFs track in people over time so a single measurement is
reasonably reflective of long-term levels [39]. Blood samples from
CaPS phase II were not available for some men with physical
performance data. There were no important differences between
the men with and without blood samples, in terms of the
confounding factors, suggesting that the complete-case analysis is
likely to have provided valid inferences. There could, however, be
a healthy survivor effect in both cohorts, due to the selective
sample of the survivors who were alive at the time of the physical
Table 4. Associations of age- and sex-standardized IGF z-scores with the flamingo test from logistic regression models.
Boyd Orr (cross-sectional associations;
n =392{) CaPS (prospective associations; n =725{)
Boyd Orr and CaPS combined{
(n = 1,117{)
IGF z-score OR1 95% CI P OR1 95% CI P OR1 95% CI P
Minimally adjusted models"
IGF-I 0.88 (0.65, 1.20) 0.4 0.87 (0.73, 1.04) 0.13 0.87 (0.75, 1.01) 0.076
IGF-II 1.05 (0.80, 1.37) 0.7 1.03 (0.87, 1.23) 0.7 1.04 (0.90, 1.20) 0.7
IGFBP-2* 1.08 (0.81, 1.45) 0.6 - - - - - -
IGFBP-3 0.94 (0.72, 1.23) 0.7 0.97 (0.82, 1.16) 0.8 0.96 (0.86, 1.11) 0.5
IGF-I:BP-3 0.88 (0.65, 1.20) 0.4 0.94 (0.79, 1.13) 0.5 0.92 (0.80, 1.17) 0.3
Insulin* 1.06 (0.79, 1.43) 0.7 1.16 (0.99, 1.35) 0.059 1.13 (0.99, 1.19) 0.069
Confounder adjusted models"
IGF-I 0.92 (0.66, 1.27) 0.6 0.88 (0.73, 1.06) 0.17 0.89 (0.76, 1.03) 0.10
IGF-II 1.02 (0.76, 1.36) 0.9 1.06 (0.88, 1.27) 0.5 1.04 (0.90, 1.21) 0.6
IGFBP-2* 1.05 (0.79, 1.40) 0.7 - - - - - -
IGFBP-3 0.92 (0.70, 1.20) 0.5 0.97 (0.81, 1.17) 0.8 0.96 (0.83, 1.11) 0.6
IGF-I:BP-3 0.95 (0.69, 1.30) 0.7 0.95 (0.79, 1.15) 0.6 0.94 (0.81, 1.09) 0.4
Insulin* 0.94 (0.70, 1.25) 0.7 1.16 (0.99, 1.35) 0.063 1.13 (0.98, 1.29) 0.084
Additionally controlling for BMI and co-morbidities"
IGF-I 0.92 (0.66, 1.30) 0.6 0.92 (0.75, 1.12) 0.4 0.90 (0.77, 1.06) 0.2
IGF-II 1.03 (0.78, 1.37) 0.8 1.04 (0.87, 1.26) 0.7 1.02 (0.87, 1.19) 0.8
IGFBP-2* 1.30 (0.94, 1.80) 0.11 - - - - - -
IGFBP-3 0.91 (0.69, 1.21) 0.5 0.92 (0.80, 1.15) 0.4 0.92 (0.79, 1.07) 0.3
IGF-I:BP-3 0.96 (0.69, 1.33) 0.8 1.02 (0.82, 1.18) 0.9 0.98 (0.84, 1.13) 0.8
Insulin* 0.73 (0.51, 1.05) 0.093 1.08 (0.94, 1.29) 0.4 1.01 (0.87, 1.17) 0.9
*IGFBP-2 and insulin were natural log transformed before standardizing due to skewed distributions.
{Sample sizes are based on complete-case analyses for all confounders: Boyd Orr IGFs n = 392, insulin n = 358; CaPS IGFs n = 725, insulin n = 959.
{Data were combined if there was no evidence the association differed between the cohorts.
1An odds ratio (OR) .1 indicates a relative increase in odds of poor balance; an odds ratio ,1 indicates a relative decrease in odds of poor balance.
"Minimal adjusted models control for age at performance test and sex (Boyd Orr); confounder adjusted models additionally control for research centre, adult social class,
diet variables (milk intake, calcium, protein, fat and total energy), exercise, smoking, alcohol consumption; fully adjusted models additionally control for body mass
index (BMI) at the time of IGF measurement and co-morbidities at the time of the physical performance tests.
doi:10.1371/journal.pone.0030096.t004
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performance tests, probably resulting in conservative estimates
between insulin/IGFs and reduced physical performance. The
effect sizes observed in this study, and other studies examining
IGFs with physical performance, were small. However, even small
changes in physical capability can impact on physical dependency,
quality of life and medical and social care needs. Times for the
flamingo test were dichotomized because no transformation
provided an approximate to the normal distribution, but the
categorization may have produced a weaker measure of true
balance ability and will have reduced statistical power. We did not
always observe consistent findings between Boyd Orr and CaPS.
This could be for a number of reasons. Firstly, CaPS was
prospective with blood samples taken approximately 19 years
before the physical performance tests, whereas in Boyd Orr blood
samples were taken at the same clinic in which physical
performance was measured. The prospective analysis may be
considered more robust, as in cross-sectional analyses it is not
possible to exclude reverse causation as a potential explanation of
associations between IGFs and physical performance. Secondly,
the timing of exposure measurement may also have implications,
as levels of IGF-I reach a peak in young adulthood and decline
continuously with increasing age. The blood samples in Boyd Orr
were taken at a mean age of 70.7 years, compared with a mean
age of 56.1 years in CaPS and it may be that associations differ by
peak IGF levels, mid-life IGF levels or the rate of IGF decline in
older age, compared to absolute late-life levels. Thirdly, differences
in sample sizes could mean that the smaller Boyd Orr study was
underpowered to pick up small effects: confidence intervals in
Boyd Orr were, on the whole, consistent with chance. Finally,
associations may have arisen by chance due to multiple testing.
If they reflect causal associations and are not due to chance,
these findings could have implications for public health interven-
tions: IGF-I has been promoted for treating diabetes, osteoporosis
and insulin resistance [40]; however, lifestyle and pharmacological
interventions are also being considered to reduce circulating levels
of IGF-1 in order to prevent cancer [41]. Potential interventions
aimed at raising IGF-I levels in older adults would need to be
carefully assessed given the possible adverse effects of raised IGF-I
levels on cancer [42]. Increased physical activity has been
proposed as a means of influencing IGF-I levels. Weight loss
and exercise schemes in people with obesity have been shown to
reduce insulin resistance [43]. Such interventions may also result
in other benefits such as increasing strength, reducing falls and
frailty in older people [4]. Milk intake [44], physical capability and
strength [37] have been associated with improved overall survival.
We conclude there was some evidence that high levels of IGF-I,
but low levels of insulin, were positively associated with improved
physical performance in old age. However, given the large
confidence intervals that included the null value, confirmation or
rebuttal of the findings in larger prospective studies is needed.
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